证券代码：600750 证券简称：江中药业 公告编号：2025-015 江中药业股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）已于 2025 年 3 月 20 日发布公 司 2024 年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经营成果 和财务状况，公司计划于 2025 年 03 月 31 日下午 15:00-16:00 举行 2024 年度业 绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2024 年度经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 03 月 31 日 15:00-16:00 （二）会议召开地点：上海证券交易所上证路演中心（网址：https://roa 会议召开时间：2025 年 03 月 ...

江中药业股份有限公司（以下简称"公司"）第九届董事会第二十次会议、 第九届监事会第十五次会议、2023 年年度股东大会审议通过《公司 2024 年预 计日常关联交易的议案》，全年预计发生日常关联交易 83,173 万元，实际发生 日常关联交易 60,512 万元，其中，单项实际发生金额超过预计金额达到 300 万 元以上的各类关联交易，合计金额 453 万元。本次单项日常关联交易超出金额 无须提交股东大会审议。 公司独立董事 2025 年第三次专门会议审议通过本关联交易事项，认为公司 发生的日常关联交易建立在关联各方充分协商的基础上，所追认的 2024 年度日 常关联交易是公司基于正常生产经营所需发生的关联交易，在平等、互利基础 上进行，程序合法有效，交易行为真实合理，未损害公司和股东利益。同意将 该议案提交董事会审议。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 证券代码：600750 证券简称：江中药业 公告编号：2025-009 江中药业股份有限公司 关于追认 2024 年日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...

请务必阅读正文之后的免责条款部分 政策提振有望带动消费医疗复苏 [Table_Industry] 医药 ——《提振消费专项行动方案》政策点评 | [table_Authors] 丁丹(分析师) | 赵峻峰(分析师) | 张拓(分析师) | | | | --- | --- | --- | --- | --- | | 0755-23976735 | 0755-23976629 | 0755-23976170 | [Table_subIndustry] 细分行业评级 | | | dingdan@gtjas.com | zhaojunfeng@gtjas.com | zhangtuo024925@gtjas.com | 医药制造业 | 增持 | | 登记编号 S0880514030001 | S0880519080017 | S0880523090003 | 医药服务业 | 增持 | 本报告导读： 近日中办、国办印发《提振消费专项行动方案》，大力提振消费有望带动消费医疗复 苏，维持行业增持评级。 投资要点： [Table_Report] 相关报告 医药《【国君医药】创新药周报 20250310- 20250314》2 ...

结构性分化，把握龙头配置价值 ——中药行业2025年2月月报 长城证券产业金融研究院 分析师：刘鹏 执业证书编号：S1070520030002 邮箱：liupeng@cgws.com 分析师：袁紫馨 执业证书编号：S1070122080041 邮箱：yuanzixin@cgws.com 评级：强大于市（维持） 2025.03.03 01 核心观点 核心观点 1、 2024年 中 药 行 业分 化加大 ，头部 效应凸 显，竞 争格局 有望重 塑 2024年多因素影响行业竞争局，头部企业优势集中，华润系（华润三九、东阿阿胶、昆药集团、江中药业）、片仔癀名贵 OTC龙头、 奇 正藏药 院内贴 膏龙头 通过品 牌壁垒 和渠道 优势普 遍实现 稳健增 长，中 小企业 受成本 端压力 、集采 政策、 医保控 费、消费 疲软等 因素共 振 陷 入 亏 损 或利润 同比下 滑，行 业整体 承压， 2025年 业 绩 压 力减弱 下弹性 有望释 放 2、 估 值 与复盘 • 2月中药板块下跌1.15%， 大 幅 跑输 沪深300和 SW 医 药 生 物指数 ，主要 系科技 成长股 资金虹 吸效应 及"AI+医 疗" 关 注 景 ...

Investment Rating - The report maintains a strong investment rating for the biopharmaceutical industry, particularly for the traditional Chinese medicine (TCM) sector, which is expected to benefit from multiple factors in 2025 [2]. Core Insights - The TCM sector is anticipated to experience a gradual reduction in performance pressure in 2025, driven by factors such as improved earnings, favorable policies, decreasing costs, rising demand, and consolidation within the industry [4][6]. - The report identifies five main investment opportunities within the TCM sector, including high-end OTC products, state-owned enterprise reforms, hospital-based TCM, dividend-paying assets, and turnaround situations for struggling companies [4][7]. Summary by Sections 1. Performance Outlook - The TCM sector faced overall revenue decline in 2024, with a total revenue of 270.61 billion yuan, down 3.28% year-on-year, and a net profit of 29.88 billion yuan, down 8.55% year-on-year [10]. - The number of companies forecasting negative net profit growth in 2024 is 22 out of 34, while only 12 companies expect positive growth [16]. 2. Policy Developments - The third batch of national TCM procurement results showed an average price reduction of 63%, but the impact on listed companies is limited due to the small number of affected products [20]. - A new essential drug list is expected to be released in 2025, which may include more TCM products, enhancing their market presence [24]. 3. Cost Factors - The TCM material price index has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies and improve their gross margins starting in 2025 [28]. 4. Demand Dynamics - The recent increase in flu cases has driven demand for related treatment products, leading to a quicker clearance of inventory for cold and cough medications [34]. 5. Competitive Landscape - The TCM industry is experiencing frequent mergers and acquisitions, which are likely to enhance industry concentration and provide performance flexibility for related listed companies [39]. 6. Investment Opportunities - The report highlights five key investment themes: 1. High-end OTC TCM products, particularly those using natural bezoar as a key ingredient, are expected to see improved margins as supply stabilizes [45][54]. 2. State-owned enterprise reforms are anticipated to yield positive changes in management and strategic planning [7]. 3. Hospital-based TCM products are expected to gain market share due to regulatory support [7]. 4. Companies with strong cash flow and high dividend potential are viewed favorably [7]. 5. Companies currently facing challenges are expected to improve as inventory pressures ease [7]. 7. Recommended Stocks - The report suggests monitoring companies such as Kunming Pharmaceutical, Tongrentang, Darentang, Jiangzhong Pharmaceutical, Dong'e Ejiao, China Resources Sanjiu, Yunnan Baiyao, Tianshili, Fangsheng Pharmaceutical, and others for potential investment opportunities [4].

Investment Rating - The report maintains a rating of "Accumulate" for Jiangzhong Pharmaceutical [1] Core Views - Jiangzhong Pharmaceutical's Q3 2024 results show stable profit growth, but the health business needs recovery. The company achieved a revenue of 2.972 billion yuan in the first three quarters of 2024, a year-on-year decrease of 8.19%, while the net profit attributable to shareholders was 634 million yuan, an increase of 7.09% year-on-year [2][3] Financial Performance Summary - Revenue for 2022 was 3.885 billion yuan, with a growth rate of 35.2%. In 2023, revenue is projected at 4.390 billion yuan, reflecting a growth rate of 13.0%. However, a decline of 2.6% is expected in 2024, with revenues estimated at 4.275 billion yuan. The company anticipates a recovery in 2025 and 2026, with revenues of 4.756 billion yuan and 5.425 billion yuan, respectively, representing growth rates of 11.3% and 14.1% [1][5] - The net profit attributable to shareholders for 2022 was 598 million yuan, with a growth rate of 18.3%. The net profit for 2023 is expected to be 708 million yuan, with a growth rate of 18.4%. The company forecasts net profits of 795 million yuan, 902 million yuan, and 1.038 billion yuan for 2024, 2025, and 2026, respectively, with growth rates of 12.3%, 13.4%, and 15.1% [1][5] - The overall gross margin for Q3 2024 decreased by 2.97 percentage points to 63.94%. The gross margins for OTC, prescription drugs, and health products were 72.32%, 43.29%, and 23.62%, respectively, with year-on-year changes of +0.53, -15.39, and -25.32 percentage points [3] Business Segment Performance - The OTC segment generated revenue of 2.335 billion yuan, a year-on-year increase of 2.78%, accounting for 78.57% of total revenue, which is an increase of 6.25 percentage points. The prescription drug segment saw revenue of 365 million yuan, a decline of 25.10%, primarily due to changes in product structure from unsuccessful bids in centralized procurement. The health business generated revenue of 249 million yuan, a significant decrease of 45.73% due to slower expansion and product adjustments [2][3] Future Outlook - The report projects revenues of 4.275 billion yuan, 4.756 billion yuan, and 5.425 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 795 million yuan, 902 million yuan, and 1.038 billion yuan. The expected P/E ratios for these years are 17.8, 15.7, and 13.7, respectively [3][5]

Investment Rating - The report maintains a "Buy" rating for Jiangzhong Pharmaceutical, with an expected price increase of 5% to 15% relative to the industry index over the next six months [8]. Core Views - The report highlights the confidence in the company's long-term development, as evidenced by the controlling shareholder's plan to increase their stake in the company, with a total investment amount between 60 million and 120 million RMB [2]. - Jiangzhong Pharmaceutical is recognized as a high-dividend and quality OTC enterprise focusing on the gastrointestinal field, with plans for category expansion and channel enhancement to drive revenue growth [2]. - The company is expected to achieve revenues of 4.275 billion, 4.756 billion, and 5.425 billion RMB for 2024, 2025, and 2026 respectively, with corresponding net profits of 795 million, 902 million, and 1.038 billion RMB [2]. Financial Summary - Revenue for 2022 was 3.885 billion RMB, with a year-on-year growth rate of 35.2%. The forecast for 2023 is 4.390 billion RMB, reflecting a growth rate of 13.0%, followed by a slight decline to 4.275 billion RMB in 2024 [1]. - The net profit attributable to the parent company for 2022 was 598 million RMB, with a growth rate of 18.3%. The forecast for 2023 is 708 million RMB, with a growth rate of 18.4%, and is expected to reach 795 million RMB in 2024, reflecting a growth rate of 12.3% [1]. - The report projects a return on equity (ROE) of 17.6% for 2024, increasing to 18.3% by 2026 [1].

证券研究报告 | 公司动态点评 2024 年 08 月 22 日 江中药业（600750.SH） 2024Q2 利润增速放缓，积极进行现金分红 | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------|-------|-------|-------|-------|-------|------------------------------------|-----------| | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | 增持（维持评级） | | | 营业收入（百万元） | 3,885 | 4,390 | 4,275 | 4,756 | 5,425 | 股票信息 | | | 增长率 yoy （ % ） | 35.2 | 13.0 | -2.6 | 11.3 | 14.1 | | | | 归母净利润（百万元） | 598 | 708 | 795 | 902 | 1,038 | 行业 | 医药 | | 增长率 yoy （ % ） | 18.3 | 18.4 | 12.3 ...

证券代码：600750 证券简称：江中药业 公告编号：2024-042 江中药业股份有限公司 关于召开 2024 年第二次临时股东大会的通知 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 13 日 至 2024 年 9 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2024 年 9 月 13 日 14 点 50 分 召开地点：江西省南昌市高新开发区火炬大街 788 号公司会议室 股东大会召开日期：2024年9月13日 本次股东大会采用的网络投票系统：上海证券 ...

证券代码：600750 证券简称：江中药业 公告编号：2024-034 江中药业股份有限公司 关于 2024 年度"提质增效重回报"行动方案 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为深入贯彻党的二十大和中央金融工作会议精神，江中药业股份有限公司 （以下简称"公司"）始终践行"以投资者为本"的发展理念，促进内在价值与 市场价值相匹配，维护公司全体股东利益，增强投资者对公司的理解与信任。基 于对公司未来发展前景的信心和对公司价值的认可，公司特制定《2024 年度"提 质增效重回报"行动方案》，具体内容详见公司 2024 年 4 月 27 日披露于上海证 券交易所网站（www.sse.com.cn）的《关于公司 2024 年度"提质增效重回报" 行动方案》。现将进展情况公告如下： 一、聚焦主责主业，提高核心竞争力 公司围绕"十四五"战略规划，以"让人类充分享受健康的快乐"为使命， 以"中医药传承与创新的引领者"为愿景，立足中医药行业，走品牌与创新驱动 之路，致力于改善人民的健康生活，成为大众信赖与尊重的企 ...